Samsung BioLogics IPO Price, Capital Investment Plan & Valuation Issue
In a regulatory filing (last Friday), Samsung Biologics announced its plan to raise ₩1.23tril (US$1.12bil) of new shares. Samsung BioLogics plans...
279 Views
More Harsh Reality from Teva
U.S. healthcare industry leaders from across the spectrum of industry segments continue to downplay the near-term adoption of biosimilars in the...
198 Views
US$9 Billion Valuation Is Rarefied Air
Samsung's proposed ~US$9 billion valuation for Samsung BioLogics would out the latter in a very select company: a US$9 billion market cap for a...
247 Views
Samsung BioLogics IPO Valuation Debate
Samsung BioLogics, Samsung Group's contract manufacturing organization (CMO) of bio logic drugs, is expected to seek preliminary approval from...
299 Views
SillaJen's December IPO: Valuation, Growth Expectation and IPO Timing
SillaJen Biotherapeutics (established in 2006) is indeed a rare breed in Korean pharmaceutical world. It is not a generic drug maker. It is not a...
3.4k Views